Efficacy of combined gemcitabine, oxaliplatin and pegaspargase (P-gemox regimen) in patients with newly diagnosed advanced-stage or relapsed/refractory extranodal NK/T-cell lymphoma

Jing-hua Wang\textsuperscript{1,2,3,*}, Liang Wang\textsuperscript{1,2,3,*}, Cheng-cheng Liu\textsuperscript{1,2,3,*}, Zhong-jun Xia\textsuperscript{1,2,3}, Hui-qiang Huang\textsuperscript{2,3,4}, Tong-yu Lin\textsuperscript{2,3,4}, Wen-qi Jiang\textsuperscript{2,3,4}, Yue Lu\textsuperscript{1,2,3}

\textsuperscript{1}Department of Hematologic Oncology, Sun Yat-sen University Cancer Center, Guangzhou, 510060, People’s Republic of China
\textsuperscript{2}State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510060, People’s Republic of China
\textsuperscript{3}Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510060, People’s Republic of China
\textsuperscript{4}Department of Medical Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People’s Republic of China

*These authors contributed equally to this work

Correspondence to: Yue Lu, email: yuelv304@yahoo.com

Keywords: extranodal NK/T-cell lymphoma, gemcitabine, oxaliplatin, pegaspargase, adverse effects

Received: November 02, 2015 \hspace{1cm} Accepted: March 18, 2016 \hspace{1cm} Published: April 08, 2016

ABSTRACT

Extranodal natural killer/T-cell lymphoma (ENKTL) is an aggressive neoplasm with a poor outcome. Asparaginase-based regimens are recommended for patients with advanced-stage or relapsed/refractory ENKTL. We retrospectively investigated the efficacy and toxicity of combined gemcitabine, oxaliplatin, and pegaspargase (P-gemox) in these patients. A total of 35 patients with newly diagnosed stage III–IV, relapsed or refractory ENKTL were treated with 2 to 8 cycles of P-gemox: gemcitabine (1250 mg/m\textsuperscript{2}) and oxaliplatin (85 mg/m\textsuperscript{2}) injected intravenously and pegaspargase (2500 IU/m\textsuperscript{2}) injected intramuscularly on day 1 and repeated every 2 weeks. Upon completion of treatment, the overall response rate was 80.0%, with a complete response in 51.4% of patients. The 1-, 2- and 3- year progression-free survival rates were 45.0%, 38.6% and 38.6%, and overall survival rates were 76.8%, 64.7% and 64.7%, respectively. Patients who attained a complete response showed better progression-free survival than those without a complete response ($p = 0.01$). The major adverse effects were hematologic toxicity and liver dysfunction. Grade 3/4 leucopenia and neutropenia occurred in 40.0% of patients. No treatment-related deaths occurred. These results indicate the P-gemox regimen is a safe and effective treatment for patients with newly diagnosed advanced-stage or relapsed/refractory ENKTL. We anticipate future prospective trials will confirm the efficacy.

INTRODUCTION

Extranodal natural killer (NK)/T-cell lymphoma (ENKTL) is a distinct clinicopathological entity in the WHO classification of lymphoid neoplasms [1]. ENKTL is diagnosed more commonly in Asia and Latin America than in Western countries [2] and accounts for 5%–10% of all malignant lymphomas in China [3]. In more than 80% of cases, ENKTL originates in the nasal and upper airway region [2, 4, 5]. However, a similar disease also arises at extranasal sites, such as the skin, soft tissue, gastrointestinal tract, testis, and brain [2, 5, 6]. ENKTL is a highly invasive tumor with a short doubling time and poor prognosis. Because of its rarity, limited geographic distribution, and paucity of multicenter prospective clinical trials, the optimal first-line therapy for ENKTL continues to evolve. Systemic chemotherapy combined with involved-field radiotherapy is recommended for localized ENKTL [7] and yields a long-term survival rate of 70–80% [8, 9]. Patients with advanced-stage or relapsed/refractory ENKTL follow an extremely aggressive clinical course [10], and chemotherapy remains the mainstay treatment.
However, the conventional chemotherapy regimens based on CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) give unsatisfactory responses, and survival beyond 1 year is extremely rare among patients with advanced-stage ENKTL [2, 11–13]. The poor outcome is in part because ENKTL tumor cells express P-glycoprotein, which mediates tumor multidrug resistance (MDR) [14–16].

L-Asparaginase has a unique anti-tumor mechanism that is not affected by P-glycoprotein: tumor cells unable to synthesize L-asparagine die when their stores of L-asparagine are depleted by L-asparaginase [17, 18]. Moreover, L-asparaginase exhibits anti-tumor activity against NK cell tumors in vitro and in vivo [17, 18]. The first study of the clinical efficacy of L-asparaginase in refractory or relapsed ENKTL was published by Yong et al. in 2000 [19]. Since then, additional L-asparaginase-based regimens, like combined dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) [20, 21] and combined asparaginase, methotrexate, and dexamethasone (AspaMetDex) [22], have emerged as promising treatments for advanced-stage and relapsed/refractory ENKTL. However, the SMILE regimen is associated with unacceptable toxicities, and the efficacy of the AspaMetDex regimen requires further investigation in additional clinical trials. At our center, Wang et al. attempted to use a combined gemcitabine, oxaliplatin and L-Asparaginase (GELOX) regimen for stage IE/IIE ENKTL [23]. None of the agents included in the GELOX regimen were affected by P-glycoprotein, and it yielded promising results. Guo et al. also demonstrated the efficacy of this regimen [24]. However, the efficacy of this regimen against advanced-stage and relapsed/refractory ENKTL is not clear.

Pegylated asparaginase (pegaspargase), a form of Escherichia coli L-asparaginase that is covalently linked to polyethylene glycol, has proven effective against acute lymphoblastic leukemia and ENKTL with less toxicity and a longer half-life than free L-asparaginase [25, 26]. We therefore conducted a retrospective study to evaluate the treatment outcomes and safety profile of a P-gemox regimen composed of gemcitabine, oxaliplatin and pegaspargase for newly diagnosed advanced-stage and relapsed/refractory ENKTL cases at a single institution.

RESULTS

Patient characteristics

The patient characteristics are listed in Table 1. The median age was 38 years (range, 16 to 65 years), and the male:female ratio was about 2:1. Nineteen patients were newly diagnosed with advanced-stage ENKTL, and 16 had relapsed/refractory disease. The primary involvement site was the upper aerodigestive tract (nasal cavity, nasopharynx and tonsils) in 24 patients. Twenty-one patients (60%) had systemic B symptoms, and 15 patients (42.8%) had elevated levels of LDH. The distribution of IPI scores included 10 patients (28.6%) with IPI scores of 0–1 (low-risk group) and 25 (71.3%) with IPI scores of 2–4 (intermediate-risk or high-risk group). For relapsed/refractory patients, previous treatments included anthracycline-containing regimens (CHOP or CHOP-like regimens) alone (n = 9) or followed by radiotherapy (n = 4), a concomitant 2/3DeVIC regimen (dexamethasone, etoposide, ifosfamide, and carboplatin) or a VIPD regimen (etoposide, ifosfamide, cisplatin, and dexamethasone) and radiotherapy (n = 2), and radiotherapy alone (n = 1).

Treatment and response

The total cycles of P-gemox regimen received by all patients were 157, with a median of 5 cycles per patient (range, 2–8 cycles), and pegaspargase was administrated in 155 of the 157 cycles. During the treatment, four patients went off the treatment because of severe hematological toxicity (n = 3), abnormal liver function (n = 1) or hypofibrinogenemia (n = 2). At the interim assessment after 2 cycles of P-gemox, there were 9 CRs (25.7%), 24 PRs (68.6%), 1 SD (2.9%) and 1 PD (2.9%). Eleven patients received additional primary involved-field radiotherapy at a median dose of 50 Gy after chemotherapy. Seven patients underwent ASCT after achieving interim CR or PR. As shown in Table 2, upon treatment completion, the CR rate was improved to 51.4% (18 of 35 patients), and the PR rate was 28.6% (10 of 35 patients), yielding an ORR of 80.0%. On the other hand, one patient showed SD (2.9%), and six patients had PD (17.1%). Of the 19 patients with newly diagnosed advanced-stage ENKTL, the ORR after P-gemox chemotherapy was 78.9%, with a CR rate of 42.1%. Similarly, of the 16 patients with relapsed or refractory ENKTL, the ORR was 81.3% with a CR rate of 62.5%. There were no differences in either the ORR or CR rate between patients with newly diagnosed advanced-stage disease and those with relapsed/refractory disease. There were no significant clinicopathologic factors associated with CR or ORR (data not shown).

Survival

After a median follow-up period of 28 months (range, 9–50 months), the 1-, 2- and 3-year PFS rates were 45.0%, 38.6% and 38.6%, and the OS rates were 76.8%, 64.7% and 64.7%, respectively (Figure 1). During the follow-up period, 11 patients died due to disease progression. Of the seven patients who received ASCT, four were still alive with a persistent CR, while three relapsed and died due to disease progression by the end of follow-up. The median PFS and OS of these seven patients were 15 and 16 months, respectively. Patients who received ASCT tended to show better PFS (p = 0.18) and OS (p = 0.66), but the difference was not statistically significant (Figure 2).
Table 1: Characteristics of 35 patients with ENKTL treated with P-gemox

| Characteristic                          | No. of Patients | %   |
|----------------------------------------|-----------------|-----|
| Age, years                             |                 |     |
| 18–30                                  | 13              | 37.1|
| 31–50                                  | 15              | 42.9|
| > 50                                   | 7               | 20.0|
| Gender                                 |                 |     |
| Male                                   | 23              | 65.7|
| Female                                 | 12              | 34.3|
| B symptoms                             |                 |     |
| Present                                | 21              | 60  |
| Absent                                 | 14              | 40  |
| Primary site                           |                 |     |
| Upper aerodigestive tract              | 24              | 68.6|
| Extra-upper aerodigestive tract        | 11              | 31.4|
| ECOG PS                                |                 |     |
| 0                                      | 25              | 71.4|
| 1                                      | 10              | 28.6|
| Disease status                         |                 |     |
| Newly diagnosed                        | 19              | 54.3|
| Relapsed/Refractory                    | 16              | 45.7|
| Ann Arbor stage                        |                 |     |
| I/II                                   | 8               | 22.8|
| III/IV                                 | 27              | 77.1|
| IPI score                              |                 |     |
| 0                                      | 5               | 14.3|
| 1                                      | 5               | 14.3|
| 2                                      | 13              | 37.1|
| 3                                      | 11              | 31.4|
| 4                                      | 1               | 2.8 |
| KPI score                              |                 |     |
| 0                                      | 3               | 8.6 |
| 1                                      | 5               | 14.3|
| 2                                      | 18              | 51.4|
| 3                                      | 6               | 17.1|
| 4                                      | 3               | 8.6 |
| sLDH                                   |                 |     |
| Normal                                 | 17              | 48.6|
| Increased                              | 15              | 42.8|

Abbreviations and note: P-gemox, gemcitabine, oxaliplatin and pegaspargase; ECOG PS, Eastern Cooperative Oncology Group performance status; IPI, International Prognostic Index; sLDH, serum lactate dehydrogenase; B symptoms include unexplained fever with temperature above 38°C, night sweats or weight loss more than 10% within 6 months.
Adverse effects

Treatment-related adverse effects are shown in Table 3. The most common adverse effect of the P-gemox regimen was hematological toxicity. However, non-hematologic toxicities were also frequent, though most reported cases were mild in severity. Mild coagulation abnormalities, which were reflected by prolongation of the activated partial thromboplastin time (APTT), were observed in 17 patients. Seven patients developed fibrinogen deficiencies, most of which were grade 1/2. Hepatic transaminase elevation was seen in 85.7% of the patients, but most were grade 1/2. After administration of symptomatic treatment, liver function and coagulation abnormalities recovered to normal or near normal before the next cycle of chemotherapy. Serious gastrointestinal toxicity was infrequent, and there were only two (5.8%) patients who presented with grade 3/4 nausea, emesis or diarrhea. All adverse events were manageable with supportive care. One patient developed left upper limb deep venous thrombosis and revascularization was achieved following treatment using an anticoagulant.

Table 2: Rates of responses to the P-gemox regimen by the disease state

| Response | All Patients (N = 35) | Newly diagnosed advanced-stage (n = 19) | Relapsed/Refractory (n = 16) |
|----------|----------------------|---------------------------------------|-----------------------------|
| CR (%)   | 18 (51.4)            | 8 (42.1)                              | 10 (62.5)                   |
| PR (%)   | 10 (28.6)            | 7 (36.8)                              | 3 (18.8)                    |
| SD (%)   | 1 (2.9)              | 1 (5.3)                               | 0 (0)                       |
| PD (%)   | 6 (17.1)             | 3 (15.8)                              | 3 (18.8)                    |
| ORR (%)  | 28 (80.0)            | 15 (78.9)                             | 13 (81.3)                   |

Abbreviations: P-gemox, gemcitabine, oxaliplatin and pegaspargase; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; ORR, overall response rate.

Figure 1: Survival curves for 35 ENKTL patients treated with the P-gemox regimen.
Other noticeable toxicities included hypertriglyceridemia, hyperglycemia, hypoglycemia and hypoalbuminemia. No allergic reactions or pancreatitis were observed. No treatment-related deaths occurred.

**DISCUSSION**

For patients with advanced stage, relapsed, or refractory ENKTL, chemotherapy is a mainstay treatment. This study demonstrates that the P-gemox regimen is an effective and tolerable treatment strategy for this patient population. A number of L-asparaginase-based regimens have yielded promising results in patients with advanced stage or relapsed/refractory ENKTL in recent years [20, 22, 27–29]. Moreover, pegaspargase is associated with a lower incidence of anti-asparaginase antibody induction and exhibits more prolonged asparagine depletion as well as easier administration, as only a single treatment every 2 weeks is required.

In recent years, additional L-asparaginase-based regimens, such as SMILE and AspaMetDex, have yielded promising results in advanced-stage and relapsed/refractory ENKTL. Table 4 summarizes the latest published results from L-asparaginase-based regimens for this disease. From this table, we can see that the treatment responses and survival outcomes obtained with the P-gemox regimen are superior or similar to those achieved with the SMILE [20, 21] and AspaMetDex [22] regimens, which is indicative of the excellent antitumor effect of the P-gemox regimen.
Interestingly, the responses of patients receiving P-gemox as upfront therapy for newly diagnosed advanced-stage ENKTL were similar to those of patients receiving P-gemox as salvage for relapsed/refractory disease. This is usually not the case. Most other chemotherapeutic regimens are more effective in newly diagnosed than relapsed/refractory patients, probably due to P-glycoprotein-mediated MDR. As mentioned above, pegaspargase is not affected

### Table 4: Comparison of pegaspargase- or L-asparaginase-based regimens in the treatment of extranodal NK/T-cell lymphoma

| Disease status | No. | Treatment | Response | Survival | Adverse effects |
|----------------|-----|-----------|----------|----------|-----------------|
|                |     |           | ORR      | CR       | Grade 3/4 neutropenia | Grade 3/4 hepatotoxicity | Reference |
| Newly diagnosed, advanced-stage or relapsed/refractory | 35  | P-gemox ± sandwiched RT (50 Gy) | 80.0% | 51.4% | 1 y: 76.8% | 1 y: 45.0% | 40% | 11.5% | this study |
| Newly diagnosed, relapsed/refractory, any stage | 87  | SMILE ± sandwiched RT (50 Gy) | 81% | 66% | 5 y: 50% | 4 y DFS: 64% | 67% | 7% | 21 |
| Newly diagnosed, stage IV, or relapsed/refractory | 38  | SMILE | 79% | 45% | 1 y: 55% | 1 y: 53% | 100% | 32% | 20 |
| Relapsed/refractory | 19  | AspaMetDex | 78% | 61% | 2 y: 40% | 2 y: 40% | 42% | 16% | 22 |

Abbreviations: No., number; ORR, overall response rate; CR, complete remission; OS, overall survival; PFS, progression-free survival; DFS, disease-free survival; RT, radiotherapy; y, year; P-gemox, gemcitabine, oxaliplatin and pegaspargase; SMILE, methotrexate, ifosfamide, dexamethasone, etoposide, and L-asparaginase; AspaMetDex, L-asparaginase, methotrexate, and dexamethasone; GELOX, gemcitabine, oxaliplatin, and L-asparaginase.

**Figure 2:** PFS (A) and OS (B) after P-gemox regimen chemotherapy according to HSCT.
by MDR and exhibits a unique anti-tumor mechanism: tumor cells unable to synthesize asparagine die when their stores of asparagine are depleted by L-asparaginase. It will thus exhibit similar efficacy in all patients not previously treated with P-gemox. In addition, the patients who had a CR showed better PFS than those who did not, suggesting that for patients without a CR to our treatment, alternative treatments will be needed to prevent relapses.

Among the seven patients who received ASCT, four were alive with persistent CR, while three relapsed and died of their disease by the end of follow-up. Because of the relatively small sample size, it was not possible to draw a robust conclusion that ASCT consolidation improves survival. Although ASCT has been evaluated in many studies of ENKTL patients, and appears to benefit patients with advanced stage disease [39–41], the impact of ASCT in the era of asparaginase-based treatments remains unknown. Therefore, international prospective trials are needed to address issues around the benefits and timing of ASCT for the treatment of ENKTL.

Among the adverse events reported, grade 3/4 toxicities were mainly hematological. Timely administration of G-CSF was essential when patients experienced severe cytopenias after chemotherapy. Other commonly reported side effects of pegaspargase therapy include gastrointestinal disorders, liver dysfunction, coagulopathies, hypertriglyceridemia, hyperglycemia, and hypoalbuminemia [42]. In the present study, grade 1–2 toxicities were frequently related to these side effects, and could be well controlled with supportive treatments. Venous thrombosis is another known adverse event of asparaginase, and one patient developed left upper limb deep venous thrombosis during our study period, but revascularization was achieved following anticoagulant treatment. Thus, patients must be monitored closely for thrombosis during follow-up and in subsequent trials. There were no allergic reactions or pancreatitis observed in this study, and no treatment-related deaths occurred. The hematologic toxicities and liver dysfunction seen in our study were considerably milder than those reported with the SMILE and AspaMetDex regimens (Table 4). In sum, the P-gemox regimen presented acceptable toxicity profiles.

In conclusion, this study demonstrated that P-gemox is an effective and well-tolerated treatment for patients with newly diagnosed advanced-stage or relapsed/refractory ENKTL. However, this is a retrospective nature study with a relatively small sample size. Prospective randomized clinical trials will be needed to validate the long-term efficacy of the P-gemox regimen.

**MATERIALS AND METHODS**

**Patients**

From October 2010 to November 2014, a total of 35 patients with newly diagnosed stage III to IV, relapsed or refractory ENKTL who received the P-gemox regimen in Sun Yat-sen University Cancer Center were identified and included in this retrospective analysis. Clinical information was obtained through a review of medical records. The inclusion criteria for this retrospective study were as follows: (1) pathologically confirmed diagnosis of ENKTL based on the WHO “classification of Tumors of Hematopoietic and Lymphoid Tissues”; (2) Ann Arbor stage III to IV or relapsed/refractory disease; (3) no previous or concomitant malignancies; and (4) a complete set of clinical information and follow-up data. This study design was approved by the Sun Yat-sen University Cancer Center Research Ethics Board. Informed consent for the use and publication of medical information was obtained from all patients during their first visit.

Patients were staged on the basis of Ann Arbor staging system; International Prognostic Index (IPI) scores were calculated on the basis of age, Eastern Cooperative Oncology Group performance status (ECOG PS), Ann Arbor stage, serum biochemistry with lactate dehydrogenase (LDH), and the number of extranodal extensions. Positron emission tomography (PET)-CT scans, bone marrow Epstein-Barr virus-encoded small RNA (EBER) stain, and Epstein-Barr virus (EBV) DNA blood levels were not included in the routine staging investigations in the study. Follow-up information was obtained from patients’ medical records or by telephone.

**Treatment**

Patients were treated using the P-gemox regimen, which included gemcitabine (1250 mg/m²) and oxaliplatin (85 mg/m²) injected intravenously and pegaspargase (2500 IU/m²) injected intramuscularly on day 1 and repeated every 2 weeks. A maximum of 6 to 8 chemotherapy cycles were administered. During the chemotherapy intervals, patients with hematologic toxicities leading to a white blood cell count < 2.0 × 10⁹/L or absolute neutrophil count ≤ 1.0 × 10⁹/L received granulocyte-colony-stimulating factor (G-CSF) (5 μg/kg/day) until their neutrophil counts had recovered. For patients who had never been irradiated, IFRT for the primary anatomic site or residue lesion was administered after finishing all chemotherapy treatments. In addition, patients could receive autologous stem cell transplantation (ASCT) after achieving complete remission or partial remission. The decision was made according to the discretion of the treating physicians, mainly on the basis of the patient’s age, comorbidities, and patient’s wishes.

**Responses and toxicity criteria**

Treatment responses were assessed after every two cycles of chemotherapy and classified as complete response (CR), partial response (PR), stable disease (SD), or progressive disease (PD) according to the Revised Response Criteria for Lymphoma [43]. The overall response rate (ORR) was defined as the proportion of patients who achieved a CR or PR. Interim response was
assessed after two courses, and the completion response was defined as the response after the last course of P-gemox. Patients achieving an interim CR or PR continued to receive P-gemox until ASCT, relapse, or completion of all courses. Patients with SD on interim assessment may have continued to receive P-gemox, whereas patients with PD received other salvage regimens.

After the treatment was completed, patients were followed up and assessed by their oncologist in the outpatient department. Each assessment consisted of a physical examination, complete blood count, serum biochemistry (including LDH level), and either a CT scan, MRI of the involved region or PET-CT scan. Toxicity after chemotherapy was evaluated according to the National Cancer Institute Common Terminology Criteria of Adverse Events v3.0.

Statistical analysis

The primary end point was ORR at the end of treatment. The secondary end points were CR, overall survival (OS), progression-free survival (PFS) and toxicity. OS was measured from the date of the first administration of the P-gemox regimen to the date of death or the last follow-up. PFS was measured from the date of the first administration of the P-gemox regimen to the date of disease progression or death from any cause. In the statistical design, patients were not censored at the time of transplantation.

The χ² test was used for group comparisons of categorical variables. Survival analysis was performed using the Kaplan-Meier method, and curves were compared using the log-rank test. Two-tailed values of \( P < 0.05 \) were considered significant. Statistical analyses were performed by using SPSS 17.0 software.

ACKNOWLEDGMENTS

We would like to thank all of the treating physicians at Sun Yat-sen University Cancer Center for allowing us to include their patients. This work was supported by National Natural Science Foundation of China [contract/grant number: 30471976 and 81272620], Science and technology projects of Guangdong Province [contract/grant number: 2010B031600233 and 2010A090200019].

CONFLICTS OF INTEREST

The authors have declared no conflicts of interest.

REFERENCES

1. Sabattini E, Bacci F, Sagramoso C, Pileri SA. WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview. Pathological. 2010; 102:83–87.
2. Au WY, Weisenburger DD, Intragantornchai T, Nakamura S, Kim WS, Sng I, Vose J, Armitage JO, Liang R. Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project. Blood. 2009; 113: 3931–3937.
3. Li YX, Liu QF, Fang H, Qi SN, Wang H, Wang WH, Song YW, Lu J, Jin J, Wang SL, Liu YP, Lu N, Liu XF, et al. Variable clinical presentations of nasal and Waldeyer ring natural killer/T-cell lymphoma. Clin Cancer Res. 2009; 15:2905–2912.
4. Lee J, Suh C, Park YH, Ko YH, Bang SM, Lee JH, Lee DH, Huh J, Oh SY, Kwon HC, Kim HJ, Lee SI, Kim JH, et al. Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. J Clin Oncol. 2006; 24:612–618.
5. Siu LL, Chan JK, Kwong YL. Natural killer cell malignancies: clinicopathologic and molecular features. Histol Histopathol. 2002; 17:539–554.
6. Kim GE, Cho JH, Yang WI, Chung EJ, Suh CO, Park KR, Hong WP, Park IV, Hahn JS, Roh JK, Kim BS. Angiocentric lymphoma of the head and neck: patterns of systemic failure after radiation treatment. J Clin Oncol. 2000; 18:54–63.
7. Kwong YL, Anderson BO, Advani R, Kim WS, Levine AM, Lim ST. Management of T-cell and natural-killer-cell neoplasms in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol. 2009; 10: 1093–1101.
8. Kim SJ, Kim K, Kim BS, Kim CY, Suh C, Huh J, Lee SW, Kim JS, Cho J, Lee GW, Kang KM, Eom HS, Pyo HR, et al. Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-Cell Lymphoma: Consortium for Improving Survival of Lymphoma study. J Clin Oncol. 2009; 27:6027–6032.
9. Yamaguchi M, Tobinai K, Oguchi M, Ishizuka N, Kobayashi Y, Isobe Y, Ishizawa K, Maseki N, Itoh K, Usui N, Wasada I, Kinoshita T, Ohshima K, et al. Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211. J Clin Oncol. 2009; 27:5594–5600.
10. Kwong YL, Chan AC, Liang R, Chiang AK, Chinn CS, Chan TK, Todd D, Ho FC. CD56+ NK lymphomas: clinicopathological features and prognosis. Br J Haematol. 1997; 97:821–829.
11. Suzuki R, Suzumiya J, Yamaguchi M, Nakamura S, Kameoka J, Kojima H, Abe M, Kinoshita T, Yoshino T, Iwatsuki K, Kagami Y, Tsuzuki T, Kurokawa M, et al. Prognostic factors for mature natural killer (NK) cell neoplasms: aggressive NK cell leukemia and extranodal NK cell lymphoma, nasal type. Ann Oncol. 2010; 21:1032–1040.
12. Lee J, Kim WS, Park YH, Park SH, Park KW, Kang JH, Lee SS, Lee SI, Lee SH, Kim K, Jung CW, Ahn YC, Ko YH,
et al. Nasal-type NK/T-cell lymphoma: clinical features and treatment outcome. Br J Cancer. 2005; 92:1226–1230.

13. Kwong YL. Natural killer-cell malignancies: diagnosis and treatment. Leukemia. 2005; 19:2186–2194.

14. Yamaguchi M, Kita K, Miwa H, Nishii K, Oka K, Ohno T, Shirakawa S, Fukumoto M. Frequent expression of P-glycoprotein/MDR1 by nasal T-cell lymphoma cells. Cancer-Am Cancer Soc 1995; 76:2351–2356.

15. Egashira M, Kavwamata N, Sugimoto K, Kaneko T, Oshimi K. P-glycoprotein expression on normal and abnormally expanded natural killer cells and inhibition of P-glycoprotein function by cyclosporin A and its analogue, PSC833. Blood. 1999; 93:599–606.

16. Drenou B, Lamy T, Amiot L, Fardel O, Caulet-Maugendre S, Sasportes M, Diebold J, Le Prise PY, Fauchet R. CD3-CD56+ non-Hodgkin’s lymphomas with an aggressive behavior related to multidrug resistance. Blood. 1997; 89:2966–2974.

17. Obama K, Tara M, Niina K. L-asparaginase-based induction therapy for advanced extranodal NK/T-cell lymphoma. int J Hematol. 2003; 78:248–250.

18. Ando M, Sugimoto K, Kito T, Sasaki M, Mukai K, Ando J, Egashira M, Schuster SM, Oshimi K. Selective apoptosis of natural killer-cell tumours by l-asparaginase. Br J Haematol. 2005; 130:860–868.

19. Yong W, Zhang Y, Zheng W. [The efficacy of L-asparaginase in the treatment of refractory midline peripheral T-cell lymphoma]. [Article in Chinese]. Zhonghua Xue Ye Xue Za Zhi. 2000; 21:577–579.

20. Yamaguchi M, Kwong YL, Kim WS, Maeda Y, Hashimoto C, Sasportes M, Diebold J, Le Prise PY, Fauchet R. CD3-CD56+ non-Hodgkin’s lymphomas with an aggressive behavior related to multidrug resistance. Blood. 1997; 89:2966–2974.

21. Kwong YL, Kim WS, Lim ST, Kim SJ, Tang T, Tse E, Leung AYH, Chim CS. SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group. Blood. 2012; 120:2973–2980.

22. Jaccard A, Gachard N, Marin B, Roget S, Audraine M, Suarez F, Tilly H, Morschhauser F, Thieblemont C, Ysebaert L, Devidas A, Petit B, de Leval L, et al. Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase II study. Blood. 2011; 117:1834–1839.

23. Wang L, Wang Z, Chen X, Li Y, Wang K, Xia Y, Xia Z. First-line combination of gemcitabine, oxaliplatin, and L-asparaginase (GELOX) followed by involved-field radiation therapy for patients with stage IE/IIE extranodal natural killer/T-cell lymphoma. Cancer-Am Cancer Soc. 2013; 119:348–355.

24. Guo HQ, Liu L, Wang XF, Lin TY, Yao SN, Yao ZH, Yang SJ. Efficacy of gemcitabine combined with oxaliplatin, L-asparaginase and dexamethasone in patients with newly-diagnosed extranodal NK/T-cell lymphoma. Mol Clin Oncol. 2014; 2:1172–1176.

25. Escherich G, Zur SU, Zimmermann M, Horstmann MA. Clofarabine in combination with pegylated asparaginase in the frontline treatment of childhood acute lymphoblastic leukaemia: a feasibility report from the CoALL 08-09 trial. Br J Haematol. 2013; 163:240–247.

26. Muss HB, Spell N, Scudieriy D, Capizzi RL, Cooper MR, Cruz J, Jackson DV, Richards FN, Spurr CL, White DR, Et A. A phase II trial of PEG-L-asparaginase in the treatment of non-Hodgkin’s lymphoma. Invest New Drugs. 1990; 8:125–130.

27. Jaccard A, Petit B, Girault S, Suarez F, Gressin R, Zini JM, Coiteux V, Larroche C, Devidas A, Thieblemont C, Gaulard P, Marin B, Gachard N, et al. L-Asparaginase-based treatment of 15 western patients with extranodal NK/T-cell lymphoma and leukemia and a review of the literature. Ann Oncol. 2008; 20:110–116.

28. Yong W, Zheng W, Zhu J, Zhang Y, Wang X, Xie Y, Lin N, Xu B, Lu A, Li J. L-asparaginase in the treatment of refractory and relapsed extranodal NK/T-cell lymphoma, nasal type. Ann Hematol. 2009; 88:647–652.

29. Lin N, Song Y, Zheng W, Tu M, Xie Y, Wang X, Ping L, Ying Z, Zhang C, Deng L, Liu W, Zhu J. A prospective phase II study of L-asparaginase-CHOP plus radiation in newly diagnosed extranodal NK/T-cell lymphoma, nasal type. J Hematol Oncol. 2013; 6:44.

30. Dinndorf PA, Gootenberg J, Cohen MH, Keegan P, Pazdur R. FDA drug approval summary: pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL). Oncologist. 2007; 12:991–998.

31. Reyes VE, Al-Saleem T, Robu VG, Smith MR. Extranodal NK/T-cell lymphoma nasal type: Efficacy of pegaspargase. Report of two patients from the United Sates and review of literature. Leukemia Res. 2010; 34:e50–e54.

32. Zhou Z, Li X, Chen C, Li X, Zhang L, Li L, Wang X, Ma W, Fu X, Wu J, Sun Z, Zhang X, Li Z, et al. Effectiveness of gemcitabine, pegaspargase, cisplatin, and dexamethasone (DDGP) combination chemotherapy in the treatment of relapsed/refractory extranodal NK/T-cell lymphoma: a retrospective study of 17 patients. Ann Hematol. 2014; 93:1889–1894.

33. Zinzani PL, Ventrutini F, Stefoni V, Fina M, Pellegrini C, Derenzini E, Gandolfi L, Broccoli A, Argnani L, Quirini F, Pileri S, Baccarani M. Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome. Ann Oncol. 2010; 21:860–863.

34. Dong M, He XH, Liu P, Qin Y, Yang JI, Zhou SY, Yang S, Zhang CG, Gui L, Zhou LQ, Shi YK. Gemcitabine-based combination regimen in patients with peripheral T-cell lymphoma. Med Oncol. 2013; 30:351.

35. Ahn HK, Kim SJ, Hwang DW, Ko YH, Tang T, Lim ST, Kim WS. Gemcitabine alone and/or containing chemotherapy is efficient in refractory or relapsed NK/T-cell lymphoma. Invest New Drug. 2013; 31:469–472.
36. Oki Y, McLaughlin P, Pro B, Hagemeister FB, Bleyer A, Loyer E, Younes A. Phase II study of oxaliplatin in patients with recurrent or refractory non-Hodgkin lymphoma. Cancer Am Cancer Soc. 2005; 104:781–787.

37. Faivre S, Raymond E, Woynarowski JM, Cvitkovic E. Supraadditive effect of 2′,2′-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines. Cancer Chemother Pharmacol. 1999; 44:117–123.

38. Lopez A, Gutierrez A, Palacios A, Blancas I, Navarrete M, Morey M, Perello A, Alarcon J, Martinez J, Rodriguez J. GEMOX-R regimen is a highly effective salvage regimen in patients with refractory/relapping diffuse large-cell lymphoma: a phase II study. Eur J Haematol. 2008; 80:127–132.

39. Lee J, Au WY, Park MJ, Suzumiya J, Nakamura S, Kameoka J, Sakai C, Oshimi K, Kwong YL, Liang R, Yiu H, Wong KH, Cheng HC, et al. Autologous hematopoietic stem cell transplantation in extranodal natural killer/T-cell lymphoma: a multinational, multicenter, matched controlled study. Biol Blood Marrow Transplant. 2008; 14:1356–1364.

40. Yokoyama H, Yamamoto J, Tohmiya Y, Yamada MF, Ohguchi H, Ohnishi Y, Okitsu Y, Fukuhara N, Ohba-Ohtsuka R, Kohata K, Ishizawa K, Kameoka J, Harigae H. Allogeneic hematopoietic stem cell transplant following chemotherapy containing l-asparaginase as a promising treatment for patients with relapsed or refractory extranodal natural killer/T-cell lymphoma, nasal type. Leuk Lymphoma. 2010; 51:1509–1512.

41. Ennishi D, Maeda Y, Fujii N, Kondo E, Shinagawa K, Ikeda K, Ichimura K, Yoshino T, Tanimoto M. Allogeneic hematopoietic stem cell transplantation for advanced extranodal natural killer/T-cell lymphoma, nasal type. Leuk Lymphoma. 2011; 52:1255–1261.

42. Stock W, Douer D, DeAngelo DJ, Arellano M, Advani A, Damon L, Kocakosovics T, Litzow M, Ryting M, Borthakur G, Bleyer A. Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel. Leukemia. 2011; 52:2237–2253.

43. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007; 25: 579–586.